Development of a new strategy for tumor immunity activation
Project/Area Number |
16K15227
|
Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
Allocation Type | Multi-year Fund |
Research Field |
Pathological medical chemistry
|
Research Institution | Tohoku University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
張替 秀郎 東北大学, 医学系研究科, 教授 (50302146)
|
Project Period (FY) |
2016-04-01 – 2018-03-31
|
Project Status |
Completed (Fiscal Year 2017)
|
Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Keywords | 腫瘍免疫 / Tリンパ球 / Bach2 / 疲弊 |
Outline of Final Research Achievements |
Cytotoxic T cells play critical roles in eliminating tumor cells with tumor-specific antigens. Although this tumor surveillance is effective during initial phases of tumorgenesis, it eventually fail to restrict tumor progression due to exhaustion of cytotoxic T cells. In addition, regulatory T cells and suppressor myeloid cells also inhibit the cytotoxic T cell activities. Based on our previous findings that the transcription factor Bach2 is essential for the differentiation of regulatory T cells, restricting cytotoxic T cell differentiation, this study was carried out to understand potential roles of Bach2 in the process of the T cell exhaustion and to develop a new strategy to activate tumor immunity. We found that Bach2-deficient T cells showed enhanced cytotoxic T cell differentiation and activity in vitro. Furthermore, many of the genes involved in T cell activation and cytotoxic activity were more highly expressed in Bach2-deficient T cells than in wild-type cells.
|
Report
(3 results)
Research Products
(4 results)